Screening recommendations for common malignancies, such as cervical, breast, and prostate cancer, have been ques tioned in the past year, and vigorous professional, public, and private debates have ensued. For breast cancer screen ing, mammography recommendations have been rethought, most notably by the U.S. Preventive Services Task Force. 1 Their recommendations support the use of mammography, but changes have been suggested regarding the ages to begin and end screening, as well as the frequency of the screening studies. Whereas for breast cancer very few have questioned a benefit of mammography in the appropriate population and situation (however, for opposing viewpoints, see Zahl et al 2 ), the case is different regarding prostate cancer screen ing. The use of prostatespecific antigen as a screening tool has been studied and found to be of questionable benefit. 3, 4 In certain clinical situations it might even lead to more harm than benefit. A fourth group of malignancies for which scree ning procedures are commonly used is colorectal cancers. Most physicians consider that colorectal cancer screening is beneficial and underutilized. Recent articles have discussed this underutilization, but have also noted that in various clinical scenarios, there is, surprisingly, inappropriate and over utilization, particularly regarding colonoscopies. 5, 6 For instance, the U.S. Preventive Services Task Force has issued guidelines for appropriate followup colonoscopic surveil lance after initial colonoscopy, including addressing when the initial exam reveals polyps. Despite these guidelines, it is common clinical practice to perform followup colonos copies more frequently and at shorter intervals than those recommended by expert committees. 79 The controversies over breast and prostate cancer screen ings have highlighted a paradox: Inappropriate and overuse of screening tests can lead to adverse consequences, as well as incurring significant financial costs (thereby reducing financial resources that can be used for other important medical needs). Far beyond patients experiencing anxiety due to a large number of false positive screening studies, patients undergo considerable noninvasive and invasive testing, and a substantial number of patients are even treated for malignancies that would never impact on the quality or length of their lives. This unnecessary treatment scenario is widely recognized with prostate cancer, where patients undergo major procedures, not infrequently leading to incontinence and sexual dysfunction, for malignancies that would never progress in their lifetime. This is also true, though not as well known, for breast cancer. It is commonly known, exp ected and accepted that a percentage of patients will have an abnormal mammogram that will lead to further proce dures, including biopsies, which will ultimately rule out an invasive malignancy. Though this is known, it is enlighten ing to appreciate the frequency with which this occurs. Varying slightly with the age of the woman, if 1000 women were screened biennially for 10 years, approximately 200 will have an abnormal mammogram, and 60 will eventually have a biopsy. What isn't as well known is that beyond the diagnosis and recognized conundrum of ductal carcinoma in situ, a clinical situation that will not progress to invasive breast cancer in most women, there is also a substantial overdiagnosis of invasive breast cancer, 2,10,11 which then leads to treatment, including some combination of breast sur gery, radiation therapy, chemotherapy, and hormonal therapy. Though it seems counterintuitive and far beyond what one would expect, this overdiagnosis and subsequent treatment has been calculated to be as high as 30% to 40% of all the invasive breast cancers diagnosed. 10 Balancing these nega tive consequences of screening mammography, it is esti mated that the number of lives saved for every 1000 women screened for 10 years is (age 4050 years) 0.5 women, (age 5060 years) 2 women, (age 6070 years) 3 women, (age 7080 years) 2 women. 2, 10, 11 Screening controversies have arisen primarily due to the natural biological processes of these malignancies, which were not well appreciated until recently. Screening, as presently practiced, is based on the assumption that tumors, when small, are localized, and that if they are not removed while still small, they eventually grow and metastasize. Therefore, it is postulated that if they are discovered early, this metastatic spread can be prevented. However, it has become clear that not only do some tumors, such as many prostate malignancies, grow extremely slowly, but a certain percentage of tumors will spontaneously regress and disappear. 2 In addition, aggressive tumors, even if found early, might have already spread, and early diagnosis and subsequent treatment may no longer be of benefit. It is recognized that we need to find biological markers that dis tinguish indolent, localized tumors, from those that are aggressive with a stronger tendency to metastasize. This is beginning to be done with prostate malignancies, where considering factors such as the Gleason score has led to a strategy of active surveillance in many patients, as opposed to immediate surgery or radiation therapy.
Screening recommendations typically take into account only a small number of known risk factors. With colorectal cancer, risk factors usually considered include mainly age, a family or personal history of a colorectal malignancy or adv anced adenomatous polyps, inflammatory bowel disease, and certain genetic conditions, such as familial polyposis coli. Even fewer risk factors are considered for breast and espe cially prostate cancer screening recommendations. As will be discussed below in more detail, considering other common and known risk factors, individualizing and stratifying patients to a greater degree, has the potential to impact strongly on recommendations for screening.
There are important differences between screening for breast, prostate, and colorectal malignancies. The most obvi ous is whereas breast cancer screening involves imaging, and prostate cancer involves a blood test, the initial step in screening for colorectal malignancies offers choices of noninvasive, invasive, and imaging methods. As will be discussed below, since invasive screening procedures, such as colonoscopy, in colorectal cancer screening incur some level of risk and significant costs, as well as some advan tages, a choice between the screening methods is important. With this in mind, we will now discuss issues related to colorectal cancer screening.
Colorectal Cancer Screening
In discussing screening for colorectal malignancies, there are 3 distinct clinical scenarios we will address-initial screening, postpolypectomy surveillance, and recommenda tions after a normal initial colonoscopy. As there is almost universal agreement that screening for colorectal malignan cies is important in appropriate populations, we will first discuss recommendations for an average risk patient, focus ing on the choice of initial colorectal screening procedure. As clinicians, we are taught that in realworld practice, the important issue is that our patients get screened, one way or the other. Though expert committees recommend a range of acceptable approaches 12 in much of the United States this means, practically speaking, either a colonoscopy or fecal occult blood (FOB) testing with highsensitivity guaiac or immunochemical methods. However, certainly in speaking with gastroenterologists (as they are considered to have the most expertise in this area, this view filters through to most physicians), the appropriate and best colorectal cancer scre ening strategy is almost always synonymous with colo noscopy. In an average risk population, the overwhelming majority of gastroenterologists, and most physicians therefore con sider that the gold standard is a screening colonoscopy at age 50 years. But what does "average risk" mean, and what type of people are included in this "average risk" population? This population includes (a) obese, sedentary individuals with a meat/potato/soda/junk food diet, many of whom also smoke; (b) other individuals who exercise regularly, eat a vegetarian/whole food-based diet, have ideal body weight, take calcium and folic acid, and have excellent 25OH vita min D levels (all possibly associated with decreased risk of colorectal cancer); and (c) a wide range of individuals in between. In an excellent review article, important risk fac tors for advanced adenomas and colorectal malignancies (besides the traditional ones considered above of age, family history, inflammatory bowel disease, and certain genetic conditions) are considered. 13 Common risk factors such as metabolic syndrome, cigarette smoking, coronary artery disease, and diabetes can each increase risk significantly, equivalent to the risk incurred if the patient had a first degree relative with a colorectal malignancy. 13 Clearly, since "average risk" patients include patients who have many or none of the additional known risk factors, "average risk" patients are a very heterogeneous group. Yet our rec ommendations do not consider this heterogeneity.
Colonoscopy, when considering large, and especially aging populations, is not a completely benign procedure. It is certainly costly. Though studies differ, perforations can occur in 1/1000 to 2/1000 procedures even when biopsies are not performed. With biopsies, serious complications can occur in up to 7/1000 procedures, though these num bers might be lower in a healthy screening population, as opposed to patients undergoing colonoscopy for clinical indications such as bleeding. 14 Physician recommendations regarding the appropriate screening procedure can play an important role here. Few physicians doubt that the higher risk obese individuals described above would benefit from an initial screening colonoscopy. Perhaps not so obviously for the healthier patients described. They might have a better risk/benefit ratio (along with considerably lower costs) with FOB testing yearly. Maybe, for this group, the "gold stan dard" is not colonoscopy but rather annual FOB testing. Although these different screening recommendations issued by expert committees have been considered from the stand point of an "average risk" patient, the other risk factors dis cussed above, such as obesity and smoking have not been considered. In this context, the healthier population descri bed above, can be considered "low risk." By individualizing our patients further than the standard approach, expanding our view beyond high and average risk, a case can be made Integrative Cancer Therapies 9 (4) more clearly that whereas "average risk" patients with other risk factors such as obesity and smoking would benefit more from colonoscopy compared with FOB testing, the health ier type of patients described above are adequately, more safely, and perhaps more appropriately screened with lower risk and lower cost screening options (FOB testing).
Post-polypectomy surveillance
Let us now consider patients who have an initial screening colonoscopy at age 50 years. If adenomatous polyps are found, this differentiating clinical finding usually leads to a recommendation of a repeat colonoscopy in 3 to 5 years. Guidelines recommend differentiating between those patients with polyps, but who are still at lower risk (<3 polyps, <1 cm, hyperplastic polyps) and those at higher risk (>3 adenomatous polyps, >1 cm, dysplasia). It is very common for endoscopists to recommend screening more frequently than the guidelines indicate. 79, 15 In fact, the majority of colonoscopists recommend repeat colonoscopy at shorter intervals than published guidelines. Whereas some might do it because of unfamiliarity with the guidelines, many do it based on clinical judgment and opinions, which may or may not be based on evidencebased studies. 15 Importantly, their considerations are typically solely based on the colono scopic findings, without consideration for other risk factors in the individual patient. Exp anding our consideration of risk factors, there are different subgroups with similar colo noscopic findings. For instance, guidelines for repeat colonoscopic surveillance in a patient with <3 adenomatous polyps, all <1 cm, would be to repeat colonoscopy in 5 years. The recommendation by many colonoscopists, however, is to repeat the study in 3 years. In a patient with other known risk factors, such as smoking, obesity, known vitamin D deficiency, this shorter interval might be appropriate. However, in other patients without these risk factors, and with factors likely preventive of progression to colorectal cancer (diet, exercise, ideal body weight), the published guidelines of repeating the colonoscopy at 5 years could more easily, and appropriately, be recommended. If there is concern, the 5year recommendation could be aug mented by interval FOB testing in years 3 and 4. The case is similar for patients with more advanced colonoscopic findings, such as >3 adenomatous polyps, size >1 cm, and dysplasia. All these patients require close followup, but decisions about the intensity of the follow up can vary when we consider the other individual factors such as obesity, smoking, or the absence of these.
Surveillance after normal initial screening colonoscopy
About 80% of "average risk" individuals will have a normal initial colonoscopy, specifically without any polyps. This is likely higher than 80% in a healthier, "low risk" population. After a normal initial screening colonoscopy, the medical lit erature shows that there is a much lower risk for the subsequent development of a colorectal malignancy. 1621 These studies suggest that a cohort of patients with a normal initial screening colonoscopy are 50% to 75% less likely (compared with the general population) to develop colorec tal cancer in the next 10, possibly 20 years. Despite this, and analogous to the situation with postpolypectomy sur veillance, colonoscopists commonly recommend repeating a colonoscopy not after 7 to 10 years (the official recom mendation), but as early as 5 years, after patients have an initial negative screening colonoscopy. One study of 1256 patients demonstrated that, after a normal screening colo noscopy, not a single patient had a malignancy diagnosed on a repeat colonoscopy 5 years after the initial normal exam; 1.5% of these individuals had advanced polyps. 21 These 1256 patients were not individualized, but included, as in all studies, the range of obese to healthy patients dis cussed above. One would wonder if the advanced polyps developed primarily in individuals with unhealthy lifestyles and risk factors as noted above. In the individual patient with a normal initial colonoscopy (particularly for those patients with the healthy lifestyle described above), consid ering the risk/benefit ratio might suggest that repeating this procedure in the future is of questionable value, especially as the patients will be older and have more comorbidities, leading to an increased susceptibility to adverse events with colonoscopic procedures. For these patients, annual FOB testing beginning after 7 to 10 years might be preferred. On the other hand, an individual who has a negative initial colonoscopy, but has other risk factors such as smoking and obesity, should probably continue with followup colonos copies at appropriate intervals. Only by individualizing patients beyond "average risk," and knowing the published, but not as well known, evidence, can we consider these viewpoints.
This approach of individualized prescribing can also be applied to other areas of screening where controversies exist, such as mammograms (especially in women 4050 years old), and prostatespecific antigen screening. When recom mendations for screening are given, patients are typically divided into high risk, average risk, and much less frequently, low risk. Surely patients are individualized far more than 2 or 3 categories. It is clear that in some populations, screen ing colonoscopy is underutilized, whereas in other populations, it is overutilized. It is an interesting and concerning social phenomenon that healthier (and often more economically advantaged) patients, who will likely have less benefit from screening as they will have a lower incidence of malignan cies, are screened much more commonly than unhealthy patients. This is because of their higher health awareness and disparities in health care use and delivery. This disparity leads to poorer health outcomes and underutilization in one population (the disadvantaged and usually poorer), but paradoxically, likely leads to overutilization, unnecessary economic costs, and a relative increase of adverse effects as opposed to benefits, in other populations (the economically advantaged and more health conscious). It may also distort the scientific understanding as results from one population (such as a population with unhealthy lifestyle behaviors) are assumed to be similar in a very different population (with healthier lifestyle behaviors), or vice versa.
It is important to recognize that there are not any obser vational or clinical studies, to my knowledge, addressing the discussed issue of further individualization guiding our screening recommendations. These would certainly be wel comed, but the present state of knowledge requires that we base our recommendations on informed clinical judgment.
In conclusion, colorectal cancer screening procedures, especially colonoscopies, though clearly important are both under and overutilized. In addition, there is a tendency to recommend more expensive and invasive procedures (colonos copy) over less expensive noninvasive means (FOB testing). By differentiating beyond the commonly considered risk fac tors, such as family history and presence of adenomatous polyps, and considering other factors such as smoking and metabolic syndrome, we can fine tune our understanding of high, average, and low risk populations, and guide those patients at lower risk to less invasive, and lower cost screening recommendations, while continuing, and even intensifying, screening programs for those at relatively higher risk.
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